Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Amicus Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Amicus Therapeutics, Inc.’s stock price such as:

• Amicus Therapeutics, Inc.’s current stock price and volume
• Why Amicus Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for FOLD from analysts
• FOLD’s stock price momentum as measured by its relative strength

About Amicus Therapeutics, Inc. (FOLD)

Before we jump into Amicus Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Want to learn more about Amicus Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Amicus Therapeutics, Inc..

What Caused Amicus Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of November 28, 2025, there were 2 analysts who downgraded Amicus Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Amicus Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Amicus Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Amicus Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Amicus Therapeutics, Inc. (FOLD) by visiting AAII Stock Evaluator.

Relative Price Strength of Amicus Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 28, 2025, Amicus Therapeutics, Inc. has a weighted four-quarter relative price strength of 3.23%, which translates to a Momentum Score of 69 and is considered to be Strong.

Want to learn more about how Amicus Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Amicus Therapeutics, Inc. Stock Price: Bottom Line

As of December 1, 2025, Amicus Therapeutics, Inc.’s stock price is $9.915, which is down 0.15% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Amicus Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.